FARE - Food Allergy Research & Education Logo

Bioavailability of Nasal Epinephrine

Study Purpose

A Study to Compare the Bioavailability of Epinephrine following a Single Nasal Dose of FMXIN002 Microspheres Powder with Epinephrine 0.3 mg Intramuscular Injection in Adult Subjects with Seasonal Allergic Rhinitis with and without Nasal Allergen Challenge

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.

An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.

Searching Both is inclusive of interventional and observational studies.

Eligible Ages 18 Years - 55 Years
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

The following inclusion criteria will be assessed at screening (within 28 days prior to the first drug administration): 1. Non-smoking, male and female subjects from 18 to 55 years of age. 2. Documented Positive skin allergy test during the last year. 3. History of hay fever, seasonal allergies, or rhinitis. 4. BMI ≥18 and <=30 kg/m2. 5. Females may be of childbearing or non-childbearing potential:
  • - Childbearing potential: o Physically capable of becoming pregnant.
  • - Non-childbearing potential: - Surgically sterile (i.e., both ovaries removed, uterus removed, or bilateral tubal ligation); and/or.
  • - Postmenopausal (no menstrual period for at least 12 consecutive months without any other medical cause.
6. Willing to use acceptable, effective methods of contraception. 7. Able to tolerate venipuncture. 8. Be informed of the nature of the study and give written consent prior to any study procedure. 9. Willing and being able to remain in the clinic for the entire duration of the confinement period. 10. Have good intravenous access on both arms and hands.
  • -

    Exclusion Criteria:

    Known history or presence of clinically significant neurologic, hematologic, endocrine, oncologic, pulmonary, immunologic, genitourinary, psychiatric, or cardiovascular disease or any other condition which, in the opinion of the Investigator, would jeopardize the safety of the subject or impact the validity of the study results.
Known or suspected carcinoma. Known history or presence of hypersensitivity or idiosyncratic reaction to epinephrine, sulfite, other excipients of epinephrine auto-injector, or any other drug substances with similar activity. Known history or presence of clinically significant lactose, galactose, or fructose intolerance. Known history or presence of cardiac arrythmias, coronary artery disease or organic heart disease. Known history or presence of hyperthyroidism. Known history or presence of diabetes. Known history or presence of Parkinson's disease. Known history or presence of any food allergy. Presence of hepatic or renal dysfunction. Presence of nostril or septum piercing. Presence of abnormal nasal anatomy (e.g., polyps, unilateral or bilateral abnormalities of the nares, nasal turbinates, or septum including deviated septum). History of nasal surgery. Presence of a medical condition requiring regular medication (prescription and/or over-the-counter) with systemic absorption. History of drug or alcohol addiction requiring treatment or positive alcohol breath test at check-in. Any acute illness (e.g. cold, acute infection) which is considered significant by the Investigator and that has not resolved within 7 days before the first drug administration. Positive test result for HIV, Hepatitis B surface antigen, or Hepatitis C antibody. Positive test result for urine drugs of abuse (amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, methadone, opiates, phencyclidine, and tricyclic antidepressants) or urine cotinine. Difficulty fasting or consuming standard meals. Inability to communicate well with the Investigators and staff (e.g., language problem, poor mental development or impaired cerebral function). Non-cooperative or unwilling to sign consent form or unwilling to attend scheduled clinic visits and/or comply with the study protocol. Use of tobacco or nicotine-containing products within 6 months prior to drug administration. Females who:
  • - Have discontinued or changed the use of implanted, intrauterine, intravaginal, or injected hormonal contraceptives within 6 months prior to drug administration; - Have discontinued or changed the use of oral or patch hormonal contraceptives within 1 month prior to drug administration; - Are pregnant (serum hCG consistent with pregnancy); or.
  • - Are lactating.
Donation or loss of whole blood (including clinical trials):
  • - ≥50 mL and <500 mL within 30 days prior to drug administration; - ≥500 mL within 56 days prior to drug administration.
Participation in a clinical trial that involved administration of an investigational medicinal product within 30 days prior to drug administration, or recent participation in a clinical investigation that, in the opinion of the Investigator, would jeopardize subject safety or the integrity of the study results. On a special diet within 30 days prior to drug administration (e.g., liquid, protein, raw food diet). Have had a tattoo or body piercing within 30 days prior to drug administration. Have clinically significant findings in vital signs measurements at screening. Systolic blood pressure increase or decrease in value by more than 20 mmHg and/or diastolic blood pressure decrease in value by more than 10 mmHg, from supine or sitting to standing position during orthostatic blood pressure measurement taken at screening. Have clinically significant findings in a 12-lead ECG. Have clinically significant abnormal laboratory values and hemoglobin <135 g/L for males or <120 g/L for females at screening. Have significant diseases at the screening. Have clinically significant findings from a physical examination. Use of the following drugs within 14 days prior to drug administration:
  • - Alpha-adrenergic blocking drugs (e.g., phentolamine); - Anti-arrhythmics; - Beta-adrenergic blocking drugs (e.g., propranolol); - Cardiac glycosides; - Diuretics; - Drugs having an effect on cytochrome P450 (CYP450); - Enzyme-altering drugs (e.g., barbiturates, phenothiazines, cimetidine, carbamazepine, etc.); - Enzyme-modifying drugs known to induce/inhibit hepatic drug metabolism; - Ergot alkaloids; - Levothyroxine sodium; - Monoamine oxidase inhibitors; - Oral or topical corticosteroids; - Phenylephrine; - Reserpine-type or clonidine-type antihypertensives; - Sodium cromoglycate; or.
  • - Tricyclic antidepressants.
Use of the following drugs within 7 days prior to drug administration:
  • - Nasal decongestants; - Nonsteroidal anti-inflammatory drugs (NSAIDs); or.
  • - Oral or topical antihistamines.

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.


Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Phase 1
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Nasus Pharma
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

Yoseph Caraco, Prof.
Principal Investigator Affiliation Hadassah Medical Center
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Overall Status Recruiting
Countries Israel

The disease, disorder, syndrome, illness, or injury that is being studied.

Additional Details

Study Design: Open-label, single-dose, two-period, three-treatment, fixed-sequence, comparative bioavailability study Study Population: Non-smoking, male and female subjects, from 18 to 55 years of age with known history of hay fever, seasonal allergies, or rhinitis during the last year.

Arms & Interventions


Experimental: Adults with seasonal allergic rhinitis

Single administration of 1.6mg or 3.2 mg Epinephrine powder nasal spray, with or without allergenic challenge, and single IM 0.3 mg Epinephrine without allergenic challenge.


Drug: - Epinephrine Nasal Product, 1.6 mg

Single dose Nasal powder spray without allergen challenge

Drug: - Epinephrine nasal product, 1.6 mg + allergen

Single dose Nasal powder spray with allergen challenge

Drug: - Epinephrine Injection 0.3 mg

Intramuscular injection

Drug: - Epinephrine Nasal Product, 3.2 mg

Twice dose Nasal powder spray without allergen challenge

Drug: - Epinephrine Nasal Product, 3.2 mg + allergen

Twice dose Nasal powder spray with allergen challenge

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

International Sites

Hadassah Medical Center, Ein Kerem, Jerusalem, Israel




Hadassah Medical Center, Ein Kerem

Jerusalem, ,

Site Contact

Leah Grinfeld



The content provided on clinical trials is for informational purposes only and is not a substitute for medical consultation with your healthcare provider. We do not recommend or endorse any specific study and you are advised to discuss the information shown with your healthcare provider. While we believe the information presented on this website to be accurate at the time of writing, we do not guarantee that its contents are correct, complete, or applicable to any particular individual situation. We strongly encourage individuals to seek out appropriate medical advice and treatment from their physicians. We cannot guarantee the availability of any clinical trial listed and will not be responsible if you are considered ineligible to participate in a given clinical trial. We are also not liable for any injury arising as a result of participation.